Skip Navigation LinksHome > July 2012 - Volume 20 - Issue 4 > Development of Enteroviral Aseptic Meningitis After Rituxima...
Infectious Diseases in Clinical Practice:
doi: 10.1097/IPC.0b013e3182506ea0
Case Reports

Development of Enteroviral Aseptic Meningitis After Rituximab Treatment of Non-Hodgkin Lymphoma

Givens, Priscilla BS; Velez, Ana Paula MD*; Sandin, Ramon L. MD, MS, FCAP†‡; Quilitz, Rod E. PharmD, BCOP§; Greene, John N. MD, FACP§∥

Collapse Box


Abstract: Rituximab is a monoclonal antibody intended for the treatment of various autoimmune conditions as well as B-cell lymphoid malignancies. It is targeted to the CD20 antigen, which induces apoptosis in mature B cells, making it a useful therapeutic agent against B-cell lymphoid malignancies when used in conjunction with cytotoxic chemotherapy regimens such as cyclophosphamide, hydroxydaunorubicin (doxorubicin), Oncovin (vincristine; Hospira Inc, Lake Forest Ill), and prednisone/prednisolone. It is a very successful treatment of B-cell malignancies but causes profound immunosuppression and elevates the risk of opportunistic infections such as enterovirus meningitis. We report a case of aseptic meningitis in a patient with non-Hodgkin lymphoma after treatment with rituximab in combination with cytotoxic chemotherapy and successful treatment with intravenous immunoglobulin therapy.

© 2012 Lippincott Williams & Wilkins, Inc.

Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.